These data indicated that CIR potentiated the tumor immune microenvironment by inducing CD8+ TILs to be reprogrammed into more functionally competent cells, which was responsible for better tumor control in prostate cancer‐bearing mice treated by CIR. This evidence concerns the gene CD8A and prostate cancer.